89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference

Rhea-AI Summary

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on innovative therapies for liver and cardio-metabolic diseases, will present a corporate update at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. CEO Rohan Palekar's presentation will be available on-demand starting at 6 a.m. EST on January 11. The archived webcast can be accessed in the investor section of 89bio’s website. The company’s lead product, BIO89-100, targets nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will provide a corporate update at the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 6 a.m. EST on Monday, January 11, 2021. An archived webcast will also be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

FAQ

What is the date of the H.C. Wainwright BioConnect 2021 Conference for 89bio (ETNB)?

The H.C. Wainwright BioConnect 2021 Conference will be held from January 11-14, 2021.

Who will provide the corporate update for 89bio (ETNB) at the conference?

CEO Rohan Palekar will provide the corporate update for 89bio at the conference.

When will Rohan Palekar's presentation be available on-demand?

Rohan Palekar's presentation will be available on-demand starting at 6 a.m. EST on January 11, 2021.

Where can I access the archived webcast of 89bio's (ETNB) presentation?

The archived webcast can be accessed in the investor section of 89bio's website.

What is the focus of 89bio's (ETNB) lead product candidate, BIO89-100?

BIO89-100 is focused on treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).